A Geoffrey Beene Cancer Research Symposium is held annually, featuring renowned global speakers. The symposium is open to Memorial Sloan Kettering Cancer Center’s research community as well as members of the public.
2014
Autophagy and Cancer
Beth Levine, MD
Professor of Internal Medicine and Microbiology, University of Texas Southwestern Medical Center
Charles Cameron Sprague Distinguished Chair in Biomedical Science, Howard Hughes Medical Institute
David Sabatini, MD, PhD
Member, Whitehead Institute
Professor Biology, MIT
Investigator, Howard Hughes Medical Institute
Senior Associate Member, Broad Institute
Member, Koch Institute
Eileen White, PhD
Associate Director for Basic Science, Rutgers Cancer Institute of New Jersey
Distinguished Professor, Molecular Biology and Biochemistry
Rutgers, The State University of New Jersey
Monday, October 20, 2014
2:30 to
Zuckerman Research Center Auditorium
417 East 68th Street
New York, NY 10065
“New Approaches to Targeted Therapy” - 2013
Martin Nowak, PhD
Harvard University
Evolutionary dynamics and treatment of cancer
Robert Schlegel, PhD
Novartis Institutes for Biomedical Research
Enhancing the impact of targeted therapy through drug combinations
Louis Staudt, MD, PhD
National Cancer Institute
Lymphoma therapy based on functional and structural genomics
“Cancer Heterogeneity” - 2012
The Regulation of Melanoma Metastasis
Sean Morrison, PhD
University Of Texas Southwestern Medical Center
Intratumor Heterogeneity: Challenges and Opportunities in Personalized Medicine
Charles Swanton, MD, PhD
London Research Institute
The Many Flavors of Resistance to Anti-Cancer Drugs
Jeffrey Settleman, PhD
Genentech, Inc.
“Epigenome” - 2011
Epigenetic Clues to the Origins of Cancer
Peter W. Laird, PhD
University of Southern California
Chemical Inhibition of Bromodomains in Cancer
James E Bradner, MD
Dana-Farber Cancer Institute
Tissue-specific Interpretation by a Histone Reader
Michelle C. Barton, PhD
MD Anderson Cancer Center
“Cancer Metabolism” - 2010
Oncogenic Reprogramming of Cell Metabolism and Therapeutic Opportunities
Chi Dang, MD, PhD
Johns Hopkins
IDH Mutations in Cancer
Valeria Fantin, PhD
Agios Pharmaceuticals
An Alternative Glycolytic Pathway in Proliferating Cells Promotes Anabolic Metabolism
Matthew Vander Heiden, MD, PhD
Massachusetts Institute of Technology
“Inflammation and Cancer” - 2009
Mechanisms Regulating Pro-Tumor Immunity During Cancer Development
Lisa Coussens, PhD
University of California San Francisco
Regulation of the Immune Response in Autoimmunity and Cancer
Richard Flavell, PhD, FRS
Yale University School of Medicine
The Role of Inflammation and Stem Cells in Gastric Cancer
Timothy Wang, MD
Columbia University
“Targeted Cancer Therapies” - 2008
PI3K and Cancer Metabolism
Lewis Cantley, PhD
Harvard Medical School
Clinical Development of Novel Anti Cancer Agents: Improvement Needed
Elizabeth Eisenhauer, MD
Queen’s University
Therapeutics Targeting the PI3K/mTOR Pathway in Cancer
William Sellers, MD
Novartis Institutes of Biomedical Research
Chemical Genetic Approaches to Deciphering the PI3K/mTOR Pathway in Cancer
Kevan Shokat, PhD
University of California San Francisco
“Oncogenomics and Cancer Medicine” - 2007
Genetic and Genomic Approaches to Myeloid Malignancies
Gary Gilliland, MD, PhD
The Dana Farber Cancer Institute
Signatures for Cancer Discovery
Todd Golub, MD
The Broad Institute
Genomic Strategies for Personalized Cancer Therapy
Joseph Nevins, PhD
Duke University
Molecular Profiles Implemented in Clinical Decision Making
Laura van’t Veer, PhD
The Netherlands Cancer Institute